FDA approves Retatrutide this year?

Prediction markets put the probability at 16%: FDA approves Retatrutide this year. Currently, markets see this as unlikely (16% YES). FDA approves first gene therapy for genetic hearing loss.

What’s Happening

The U.S. Food and Drug Administration (FDA) has demonstrated a willingness to accelerate novel therapies in April 2026, approving Regeneron’s Otarmeni as the first gene therapy for genetic hearing loss on April 23. This landmark decision, which targets a rare OTOF gene mutation affecting roughly 50 U.S. births annually, signals the agency’s continued openness to breakthrough treatments for niche patient populations. The approval follows a rapid clearance process and Regeneron’s commitment to provide the therapy free of charge to eligible patients. This regulatory environment provides important context for the ongoing assessment of whether the FDA approves Retatrutide this year, as the agency has shown it can move swiftly on therapies with strong clinical data and unmet medical need. [NBC News, Apr 23]

Retatrutide, a triple-hormone receptor agonist developed by Eli Lilly, is currently under FDA review for chronic weight management and potentially type 2 diabetes. The drug has generated significant interest due to its Phase II data showing substantial weight loss, but the path to approval remains uncertain. The current probability that the FDA approves Retatrutide this year stands at 16%, reflecting market skepticism about the timeline. Key hurdles include the need for comprehensive cardiovascular outcomes data and manufacturing scale-up, which have historically delayed obesity drug approvals. The recent gene therapy approval demonstrates the FDA can act decisively, but obesity drugs face a higher evidentiary bar given the larger target population and existing treatment options. [WSJ, Apr 23]

Looking ahead, the decision on whether the FDA approves Retatrutide this year will likely hinge on the completion of ongoing Phase III trials and the submission of a rolling New Drug Application. Eli Lilly has not publicly committed to a 2026 filing date, and analysts note that the company may prioritize a 2027 submission to ensure robust data packages. The FDA’s recent approval of Cosmo Pharmaceuticals’ clascoterone for hair loss, with a planned NDA in early 2027, suggests the agency maintains standard review timelines for non-orphan indications. Investors and healthcare stakeholders will closely monitor any FDA communication or advisory committee meetings in the coming months, as these will provide the clearest signal regarding the likelihood of a 2026 approval for Retatrutide. [GEN, Apr 21]

Traded on Polymarket — $561K Volume

Polymarket prices this at 16c YES with $561K in volume. Moderate liquidity — use limit orders for positions above $1K to avoid moving the price.